The MiniMed™ 670G (670 HCL) is the first FDA-approved hybrid closed-loop insulin delivery system device for patients with type 1 diabetes (T1D). This study aimed at evaluating clinical and patient-reported outcomes (PROs) in patients with T1D utilizing this technology.

We evaluated 54 patients with T1D using the 670 HCL in real-world clinical practice (mean age 47.9±13.2 years, 57% females, BMI 28.8±5.9 kg/m2). Data were collected at baseline and after 3 months. Measures of PROs included: Pittsburgh Sleep Quality Index (PSQI), Hypoglycemia Fear Survey Worry (HFS_W) scale, and 36-Item Short-Form Health Survey (SF-36). We also measured changes in A1C after 3 months and % of time in auto-mode (% TIAM) over the two weeks preceding the 3-month visit. Regression analyses were done between these 2 parameters and PROs. Other glycemic and quality-of-life parameters were collected at 3 months and at one year but are not included in this early report.

At 3 months, A1C decreased by 0.4±0.12% from baseline (p=0.0027). Average % TIAM was 63.9±33.1%. Among all surveyed PROs, only fear of hypoglycemia and social functioning improved compared to baseline (p<0.05 for both). There was no association between changes in PROs and reduction in A1C or % TIAM.

In conclusion, patients with T1D using the MiniMed™ 670G hybrid closed-loop system in real-world clinical practice are able to improve their A1C, fear of hypoglycemia, and social functioning but not other PROs included in the SF-36 after 3 months of use. The limited improvement in some of the PROs is not associated with the reduction in A1C or % TIAM.

Disclosure

A.H. Eldib: None. E. Toschi: Advisory Panel; Self; Lexicon Pharmaceuticals, Inc. N. Mahmoud: None. M. Tasabehji: None. S. Ashrafzadeh: None. S. Tomah: Stock/Shareholder; Self; Amarin Corporation. S.E. Dhaver: None. A. Atakov-Castillo: None. A.E. Abdul-Ghani: None. K. Farkouh: None. R. Trevino: None. O. Hamdy: Advisory Panel; Self; AstraZeneca, Sanofi-Aventis. Consultant; Self; Abbott, Merck & Co., Inc. Research Support; Self; National Dairy Council. Stock/Shareholder; Self; Healthimation, LLC.

© 2019 by the American Diabetes Association.
2019
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.